Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | IMCnyeso |
Synonyms | |
Therapy Description |
IMCnyeso is a bispecific T-cell receptor based therapy that targets NY-ESO-1 and LAGE-1A and also binds to CD3, potentially resulting in increased immune response against NY-ESO1-expressing and LAGE-1A-expressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IMCnyeso | IMCnyeso is a bispecific T-cell receptor based therapy that targets NY-ESO-1 and LAGE-1A and also binds to CD3, potentially resulting in increased immune response against NY-ESO1-expressing and LAGE-1A-expressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03515551 | Phase Ib/II | IMCnyeso | Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers | Terminated | USA | GBR | CAN | 0 |